Plain-Language Summary
Plain-language reading of the public trial registries.
In short
- Very little human research on Abarelix has been registered.
- 4 registered studies in total.
- 1 is still enrolling people, so this is active research, not just history.
What kind of research
- 4 studies actually gave the peptide to volunteers and measured what happened. This is the kind of study that can show whether something works.
- About 2,299 people took part in those.
How far along it is
- 2 trials have reached phase 3 or 4 — the large, late-stage trials regulators rely on to approve a drug.
- None have published results in the medical literature yet, so the findings are not yet open to outside scrutiny.
A registered trial is a plan, not a result. Registration means a study was declared in advance; it says nothing about whether the peptide worked, and a trial can be registered and then abandoned.
Filter
Showing 4 of 4 trials for Abarelix.
Diagnosis of Pelvic Endometriosis in MRI
Zhenshen Ma
Endometriosis
Named in the study description rather than as the headline intervention — often a drug given alongside the one being tested.
The Plenaxis® Experience Study
PRAECIS Pharmaceuticals Inc.
Prostate Cancer
Study of Abarelix in Androgen-Independent Prostate Cancer Progressing After Agonist Therapy
PRAECIS Pharmaceuticals Inc.
Prostate Cancer
Abarelix Versus Goserelin Plus Bicalutamide in Patients With Advanced or Metastatic Prostate Cancer
Speciality European Pharma Limited
Prostate Cancer
Sources: ClinicalTrials.gov, the EU Clinical Trials Information System and ISRCTN, deduplicated so a study registered in more than one registry is counted once. A study is listed when Abarelix is named as an intervention. A registered trial is a plan, not a result — registration says nothing about whether the peptide worked.